Is Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Crinetics Pharmaceuticals, Inc. at current levels.
Paltusotine launch is the appetizer. The real story is atumelnant rewriting endocrine pharma from acromegaly to obesity.
Where CRNX is headed
Crinetics in 2028 looks nothing like the single-asset acromegaly story the market has spent five years pricing. Paltusotine, approved in late 2024 and now in its second full year on the US market, is on track for a $600-800M run-rate by 2028 as the oral alternative to monthly octreotide and lanreotide injections that have dominated acromegaly care since the early 1990s. That alone justifies roughly the current enterprise value. The interesting part is what sits behind it.
Read the full Compass Direction on CRNX
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $34.97).
See the full CRNX analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Crinetics Pharmaceuticals, Inc. at current levels. Paltusotine launch is the appetizer. The real story is atumelnant rewriting endocrine pharma from acromegaly to obesity.
What is CRNX's Compass Score?
Crinetics Pharmaceuticals, Inc. scores 82/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for CRNX?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the CRNX page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.